重症与非重症COVID-19患者免疫参数的动态差异

IF 2 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Discovery medicine Pub Date : 2021-03-01
Qiang Li, Wei Xu, Weixia Li, Chenlu Huang, Ling Fei, Xudong Xie, Liang Chen
{"title":"重症与非重症COVID-19患者免疫参数的动态差异","authors":"Qiang Li,&nbsp;Wei Xu,&nbsp;Weixia Li,&nbsp;Chenlu Huang,&nbsp;Ling Fei,&nbsp;Xudong Xie,&nbsp;Liang Chen","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>We aimed to compare the dynamic differences of immunological parameters between severe and non-severe COVID-19 patients.</p><p><strong>Methods: </strong>The cytokine profiles and lymphocyte subsets of 664 patients with COVID-19 (31 severe cases and 633 non-severe cases) were longitudinally analyzed.</p><p><strong>Results: </strong>Compared with non-severe cases, severe cases had a higher age (64 vs. 40 years, p<0.001), more common comorbidity (74.2% vs. 20.5%, p<0.001), and lymphopenia (0.7 vs. 1.4x109/L, p<0.001). Severe cases had markedly higher levels of IL-6, IL-8, and IL-10 from baseline to 35 days after admission than non-severe cases (p<0.001). No significant differences were observed in the dynamic levels of IL-1beta, IL-2, IL-4, IL-5, IL-12, IL-17, TNF-alpha, IFN-alpha, and IFN-gamma between severe and non-severe COVID-19 patients (p>0.05). The absolute counts of lymphocytes, CD3+ T cells, CD4+ T cells, CD8+ T cells, and CD45+ T cells were markedly lower in severe patients with COVID-19 compared with those in non-severe patients from baseline to 35 days after admission (p<0.001). No significant differences were observed in the dynamic levels of white cells count, CD19+ B cells count, and NK cells count between severe and non-severe COVID-19 patients (p>0.05). The decrease of T lymphocyte subsets reached its peak at day 1 to 3 after admission, and they gradually increased in the non-severe group, but sustained at low levels in the severe group at day 4 to 35 after admission.</p><p><strong>Conclusion: </strong>The dynamic changes of cytokine profiles and T lymphocyte subsets are related with the severity of COVID-19.</p>","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"31 163","pages":"79-87"},"PeriodicalIF":2.0000,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dynamic Differences of Immunological Parameters Between Severe and Non-severe COVID-19 Patients.\",\"authors\":\"Qiang Li,&nbsp;Wei Xu,&nbsp;Weixia Li,&nbsp;Chenlu Huang,&nbsp;Ling Fei,&nbsp;Xudong Xie,&nbsp;Liang Chen\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>We aimed to compare the dynamic differences of immunological parameters between severe and non-severe COVID-19 patients.</p><p><strong>Methods: </strong>The cytokine profiles and lymphocyte subsets of 664 patients with COVID-19 (31 severe cases and 633 non-severe cases) were longitudinally analyzed.</p><p><strong>Results: </strong>Compared with non-severe cases, severe cases had a higher age (64 vs. 40 years, p<0.001), more common comorbidity (74.2% vs. 20.5%, p<0.001), and lymphopenia (0.7 vs. 1.4x109/L, p<0.001). Severe cases had markedly higher levels of IL-6, IL-8, and IL-10 from baseline to 35 days after admission than non-severe cases (p<0.001). No significant differences were observed in the dynamic levels of IL-1beta, IL-2, IL-4, IL-5, IL-12, IL-17, TNF-alpha, IFN-alpha, and IFN-gamma between severe and non-severe COVID-19 patients (p>0.05). The absolute counts of lymphocytes, CD3+ T cells, CD4+ T cells, CD8+ T cells, and CD45+ T cells were markedly lower in severe patients with COVID-19 compared with those in non-severe patients from baseline to 35 days after admission (p<0.001). No significant differences were observed in the dynamic levels of white cells count, CD19+ B cells count, and NK cells count between severe and non-severe COVID-19 patients (p>0.05). The decrease of T lymphocyte subsets reached its peak at day 1 to 3 after admission, and they gradually increased in the non-severe group, but sustained at low levels in the severe group at day 4 to 35 after admission.</p><p><strong>Conclusion: </strong>The dynamic changes of cytokine profiles and T lymphocyte subsets are related with the severity of COVID-19.</p>\",\"PeriodicalId\":11379,\"journal\":{\"name\":\"Discovery medicine\",\"volume\":\"31 163\",\"pages\":\"79-87\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2021-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Discovery medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discovery medicine","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:比较重症与非重症COVID-19患者免疫学指标的动态差异。方法:对664例新冠肺炎患者(重症31例,非重症633例)的细胞因子谱和淋巴细胞亚群进行纵向分析。结果:重症患者年龄高于非重症患者(64岁vs 40岁,p0.05)。入院后35 d,重症患者淋巴细胞、CD3+ T细胞、CD4+ T细胞、CD8+ T细胞、CD45+ T细胞绝对计数均明显低于非重症患者(p0.05)。入院后第1 ~ 3天T淋巴细胞亚群下降达到高峰,非重症组逐渐升高,重症组入院后第4 ~ 35天维持在较低水平。结论:细胞因子谱和T淋巴细胞亚群的动态变化与COVID-19严重程度相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Dynamic Differences of Immunological Parameters Between Severe and Non-severe COVID-19 Patients.

Objective: We aimed to compare the dynamic differences of immunological parameters between severe and non-severe COVID-19 patients.

Methods: The cytokine profiles and lymphocyte subsets of 664 patients with COVID-19 (31 severe cases and 633 non-severe cases) were longitudinally analyzed.

Results: Compared with non-severe cases, severe cases had a higher age (64 vs. 40 years, p<0.001), more common comorbidity (74.2% vs. 20.5%, p<0.001), and lymphopenia (0.7 vs. 1.4x109/L, p<0.001). Severe cases had markedly higher levels of IL-6, IL-8, and IL-10 from baseline to 35 days after admission than non-severe cases (p<0.001). No significant differences were observed in the dynamic levels of IL-1beta, IL-2, IL-4, IL-5, IL-12, IL-17, TNF-alpha, IFN-alpha, and IFN-gamma between severe and non-severe COVID-19 patients (p>0.05). The absolute counts of lymphocytes, CD3+ T cells, CD4+ T cells, CD8+ T cells, and CD45+ T cells were markedly lower in severe patients with COVID-19 compared with those in non-severe patients from baseline to 35 days after admission (p<0.001). No significant differences were observed in the dynamic levels of white cells count, CD19+ B cells count, and NK cells count between severe and non-severe COVID-19 patients (p>0.05). The decrease of T lymphocyte subsets reached its peak at day 1 to 3 after admission, and they gradually increased in the non-severe group, but sustained at low levels in the severe group at day 4 to 35 after admission.

Conclusion: The dynamic changes of cytokine profiles and T lymphocyte subsets are related with the severity of COVID-19.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Discovery medicine
Discovery medicine MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
5.40
自引率
0.00%
发文量
80
审稿时长
6-12 weeks
期刊介绍: Discovery Medicine publishes novel, provocative ideas and research findings that challenge conventional notions about disease mechanisms, diagnosis, treatment, or any of the life sciences subjects. It publishes cutting-edge, reliable, and authoritative information in all branches of life sciences but primarily in the following areas: Novel therapies and diagnostics (approved or experimental); innovative ideas, research technologies, and translational research that will give rise to the next generation of new drugs and therapies; breakthrough understanding of mechanism of disease, biology, and physiology; and commercialization of biomedical discoveries pertaining to the development of new drugs, therapies, medical devices, and research technology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信